surpass-cvot tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM Frias_Tirzepatide: Overview of SURPASS Trials

Do not compensate by skipping your next scheduled dose unless a healthcare provider specifically instructs you to do so

Rather than a one-size-fits-all approach, genetic insights inform whether you're a fast responder or someone who benefits from a more gradual titration

This approach lets you confirm good tolerance before increasing the dose

The median PFS was improved compared with placebo (PboE) (3.8 months vs

For humans, that might mean less snacking but for animals who cant choose when or what they eat, that could translate into chronic hunger, discomfort, or even malnutrition.Some previous attempts to create appetite-suppressing drugs for pets have been abandoned because of welfare concerns